The COVID-19 pandemic is placing a significant additional burden on all healthcare settings. Rapid identification of COVID-19 patients is critical to enable immediate isolation to prevent the spread of infection.
Molecular tests are available for SARS-CoV-2 but have been shown to have sub-optimal sensitivity and a turnaround time of ≥ 48 hours, causing delays in diagnosis which hampers patient isolation.4-5
SARS CoV-2 antigen tests are rapid and simple, but real-world performance has concluded low sensitivity.
During viral pandemics it is also imperative to ensure that patients with bacterial infections are not missed.6
Four studies prospectively evaluated the real-world diagnostic accuracy of FebriDx® for the detection of COVID-19 in hospitalised adults.3,4,6,10
FebriDx® was highly accurate in detecting COVID-19 infections, including cases missed by SARS-CoV-2 RT-PCR.3-4
FebriDx® viral negative patients can be rapidly cohorted to non-COVID-19 areas allowing viral positive patients to be immediately isolated whilst awaiting confirmatory PCR testing.3
In a study from Careggi University Hospital, ~45% of the patients who were negative for COVID-19 had a bacterial infection. FebriDx® was able to accurately differentiate bacterial infection from COVID-19.10
“FebriDx® could be rapidly deployed as a front door triage tool in hospitals and urgent care centers to overcome current issues of delayed diagnosis from PCR testing.”4